Skip to main content

SARS-CoV-2 Infection, COVID-19

Infectious Diseases
6
Pipeline Programs
7
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
2
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 5 programs with unclassified modality

Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.

$11.9B marketMature→ Stable30 products15 companies

Key Trends

  • HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
  • Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
  • High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity

Career Verdict

Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1BIKTARVYStable
$3.2B
Gilead Sciences·Peak10.5yr
#2EPCLUSAStable
$877M
Gilead Sciences·Peak8.2yr
#3TIVICAYDeclining
$657M
GSK·Peak4.1yr
#4TRIUMEQDeclining
$632M
GSK·Peak4.1yr
#5GENVOYAStable
$626M
Gilead Sciences·Peak6.9yr

Drug Class Breakdown

Nucleoside Reverse Transcriptase Inhibitors
$5.2B(44%)

backbone of HIV treatment, stable demand

RNA Replicase Inhibitors
$1.8B(15%)

hepatitis C treatment, mature market

Cytochrome P450 3A Inhibitors
$1.4B(12%)

boosting agents in combination regimens

P-Glycoprotein Inhibitors
$343M(3%)

niche mechanism, limited growth

Career Outlook

Stable

Infectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.

Breaking In

Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.

For Experienced Professionals

Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.

In-Demand Skills

Market access and payer strategyBrand management in generic-transition environmentsManufacturing scale-up and supply chain optimizationMedical science liaison (MSL) capabilities for physician engagementHealth economics and real-world outcomes analysis

Best For

Brand ManagerMarket Access ManagerMedical Science LiaisonSales DirectorManufacturing EngineerHealth Economics Analyst

Hiring Landscape

$160K–$275K

Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.

780
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

214Growing
100Stable
61Stable
51Growing

By Department

Commercial(32%)
$275K
Engineering(16%)
$237K
Manufacturing(14%)
$160K
Research & Development(9%)
$184K

Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
Biological/Vaccine: BNT162b2 10mcgPhase 2/3Vaccine
BioNTech
BioNTechCA - San Diego
1 program
1
Biological/Vaccine: BNT162b2 10mcgPhase 2/3Vaccine1 trial
Active Trials
NCT04816643Completed11,837Est. Dec 2023
Ridgeback Biotherapeutics
1 program
1
Molnupiravir 200 mgPhase 2
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
Molnupiravir 200 mgPhase 21 trial
Active Trials
NCT04405570Completed204Est. Feb 2021
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Molnupiravir 200 mgPhase 2
MSD
MSDIreland - Ballydine
1 program
1
Molnupiravir 200 mgPhase 2
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Molnupiravir 200 mgPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioNTechBiological/Vaccine: BNT162b2 10mcg
BioTherapeutics IncMolnupiravir 200 mg

Clinical Trials (2)

Total enrollment: 12,041 patients across 2 trials

NCT04816643BioNTechBiological/Vaccine: BNT162b2 10mcg

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Start: Mar 2021Est. completion: Dec 202311,837 patients
Phase 2/3Completed

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

Start: Jun 2020Est. completion: Feb 2021204 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.